fda import alert green list glp-1 semaglutide tirzepatide 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA unveils new safeguard in

Conditions like pernicious anaemia (an autoimmune condition affecting a protein called intrinsic factor vital for B12 absorption), stomach issues (such as from reduced stomach acid or certain medications like proton pump inhibitors), intestinal disorders (like Crohns disease or coeliac disease), or even surgical removal of parts of the small intestine (e.g., gastric bypass surgery) can prevent proper absorption

The compounding pathway allows qualified patients to access the same peptide technology without the marketing costs and supply chain markups built into branded products

2 For acquired cases, lingual melanotic macules, although rare, should be considered in the differential diagnosis of pigmented lesions of the oral mucosa

doi: 10.1016/j.dsx.2018.03.002 44 McCleanPLHlscherC

Regular Monitoring: We track your progress and adjust the treatment as necessary